Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

Excellent int. results 0.5m profit and with the benefits of the Livingstone facility from this month turnover should increase quite markedly for the full year. The outlook appears to be very positive.
2517

Tepnel Life Sciences Plc (TED-AIM) Heath Care. Pharmaceuticals and biotechnology. S. P. 8.75p Market Cap 23,669m. Trade 39.

Our share club has voted to open up a position with TED on the pretext that the S.P. will do well over the next few months.

TED, the international Molecular Diagnostics and Research Products & Services group, announces that it has granted, in aggregate, 5,800,000 share awards to
certain employees (but not directors) of the Company under the Tepnel Life
Sciences plc 2006 Long Term Incentive Plan ("Long Term Incentive Plan"). The
Long Term Incentive Plan was introduced by Tepnel in August 2006 to align more
closely management incentives with the interests of shareholders by linking the award to growth in the Company's share price over the 3 year vesting period.

The 5,800,000 nil cost options granted will be released based on the growth in
the Company's share price over the period from the date of grant to the third
anniversary of the date of grant in accordance with the following table:

To find out more about TED click onto www.shareclubuk.co.uk or go to http://tepnel.com for more background information.

Turnover should be well ahead of last year if the Livingstone facility is running to form, looking forward to the finals in march, following on from the good interims.
2517

Even dear old TED is on the rise today.
2517

Good results today.
2517

Substantial underlying organic growth leading to the first year of
significant profitability and operating cash inflows
* Revenue increased by 19% to 17.8m (2006: 15.0m) and by 22% on a constant
currency basis
* Operating profit increased to 1.39m (2006: 0.05m)
* Earnings before interest, tax, depreciation and amortization (EBITDA)
increased by 192% to 2.01m (2006: 0.69m)
* First significant operating cash inflow reported at 1.72m (2006: 0.12m)
* Improvement in gross margin to 57% (2006: 54%)
* Increase in earnings per share to 0.59p (2006: 0.06p)
* Strong sales growth in the Molecular Diagnostics division driven by the
LifeMatch range of products
* Major investment in the future of the Research Products and Services
division with the completion of the new pharmaceutical facility in
Livingston, Scotland and newly launched service lines

True information taken from the Preliminary results for the year ended 31 December 2007

Highlights
Substantial underlying organic growth leading to the first year of significant profitability and operating cash inflows
Revenue increased by 19% to 17.8m (2006: 15.0m) and by 22% on a constant currency basis
Operating profit increased to 1.39m (2006: 0.05m)
Earnings before interest, tax, depreciation and amortization (EBITDA) increased by 192% to 2.01m (2006: 0.69m)
First significant operating cash inflow reported at 1.72m (2006: 0.12m)
Improvement in gross margin to 57% (2006: 54%)
Increase in earnings per share to 0.59p (2006: 0.06p)
Strong sales growth in the Molecular Diagnostics division driven by the LifeMatch range of products
Major investment in the future of the Research Products and Services division with the completion of the new pharmaceutical facility in Livingston, Scotland and newly launched service lines

(TED share price is holding it own at this time follow the true facts at www.shareclubuk.co.uk no head in the sand, no make-believe just good old fashion share trading with the company as it stands today. 5.

When I invest in a company for the first time I invest a adequate trading amount then add to the Investment as and when I can see profits coming in for myself, TED share price trades at 8.88p at that price I hold a shed load of shares. To date I have invested two times. 5.

Tepnel Life Sciences is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Our target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities. 5.

Welcome to this Tepnel Life Sciences thread, As I am a registered blind person I can only list an update each week on the thread as information comes in direct from the company, my stock broker and others in the market place. I welcome any contribution to the thread for the benefit of all

The news from the market place is that Tepnel Life Sciences share price is trading at a discounted price of 8.50p giving an opportunity to make profits on the back of the share price. Market Cap is 20.43 million.

TED is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities.

The most recent news from the company is that AXA S.A. now hold 27,732,428 voting right shares (16.27%.) of the issued shares. // the Major Investment of AXA S.A. gives a strong influence to Buy shares with TED the comfort factor. /

Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. Share price responds by trading up 0.60p to 14p.

myway-------I don't know where you obtained the sp of TED as being 14p, they were as you say up 0.62p on the day, but the sp is 9.62p. I would like to see them @ 14p and maybe we shall see that over the next 12 months or so.
2517

2517GEORGE So sorry I posted the wrong price...
Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. The Share price responded by trading up 0.75p to 6.00p since the announcement. Now I understand why AXA S. A , Holds 27,732,428 shares in the company./

myway----you still can't get it right, they have not been as low as 6p for ages.
2517

2517GORGE Today's price 9.755p.

Update I have had a telephone conversation with my contact at Tepnel Life. He informed me that the company was very pleased with business at the present time, TEDs agreement with AstraZenca interacted a major step in the companys marketing, only to be enhanced by the news that TED has signed a two year global distribution agreement with world's largest online supplier of antibodies, Abcam.

At the end of our telephone conversation I felt that the company is now well in line to take on new clients and extra business for their life sciences products. I look forward to the next announcement from the company, I will now increase my stock holdings in the company. /

one you must have

Been quite strong last couple of days, results not due until Sept, so maybe news around the corner, anyone have any idea's?
2517

I noticed this one too George: Interims to 30 June are due out tomorrow so presumably looking good

Toya, TED posted their last interims 5/9/07 I didn't realise they were due out so soon. Thanks, Good Luck.
2517

Pretty sure I read that on their website - we'll soon know!